Annexon Biosciences, Inc. ((ANNX)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Annexon Biosciences, Inc. is conducting a Phase 3 clinical study titled A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of ANX007 in Participants With Geographic Atrophy (GA). The study aims to evaluate whether monthly IVT injections of ANX007 can reduce vision loss in patients with GA secondary to age-related macular degeneration (AMD), a significant cause of blindness in older adults.
The intervention being tested is ANX007, an experimental drug administered via IVT injection, intended to slow the progression of vision loss in GA patients. A sham group will receive placebo injections to serve as a control.
This study is designed as a randomized, parallel-group, double-masked trial, meaning neither the participants nor the care providers know who receives the actual treatment. The primary goal is treatment-focused, assessing the drug’s efficacy and safety.
The study began on July 15, 2024, with primary completion expected by May 8, 2025. These dates are crucial for investors tracking the progress and potential market entry of ANX007.
The outcome of this study could significantly impact Annexon’s stock performance, as successful results may enhance investor confidence and position the company competitively in the AMD treatment market. The ongoing recruitment status indicates active progress, with further updates available on the ClinicalTrials portal.